Paris, France, September 11th 2023 – Three years after being the 1st biopharma fund to be awarded the Tibi 1 label, Jeito Capital has announced that it has been renewed in the Tibi 2 selection, confirming its role as an accelerator in the financing of technology companies specialising in the biopharmaceutical industry.
Once again being included in the Tibi 2 funds is recognition of Jeito Capital’s major development, the quality of its team and its performance in serving talented French entrepreneurs with global ambitions.
This selection also testifies to the interest shown in the healthcare and biopharma sector and in players such as Jeito Capital, who are fully committed to mobilising and developing funding for the sector to make France a leader in healthcare research, innovation and sovereignty.
Jeito Capital is thus renewing its ambition to support the most promising French and European biopharmaceutical companies with the potential to become world leaders.
“Obtaining the Tibi 2 label marks an important step for Jeito Capital and all its teams, whose talent and commitment I salute. Financing innovation and research in healthcare is what motivates us on a daily basis, because the benefits for patients are at the heart of our strategy. Whether through our investment capacity or the expertise of our teams, we are fully committed to increase the resources made available for breakthrough innovation and for French and European sovereignty. I would like to thank the initiative’s partners for their confidence and support in achieving our ambitions,” says Rafaèle Tordjman, Founder and CEO of Jeito Capital.
About Jeito Capital
Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.
For further information please contact: